Résumé
OBJECTIVE To analyze the medication reconciliation for the inpatients in cardiovascular medicine department ，to provide reference for the establishment of working mode of clinical pharmacists in the department of cardiovascular medicine and to provide a basis for clinical pharmacists and community pharmacists developing pharmaceutical care for patients after transfering to community health center. METHODS From October 2020 to September 2021，newly admitted or newly transferred inpatients with chronic disease were selected from Shiyan People ’s Hospital of Shenzhen Bao ’an District. Medication reconciliation was conducted by clinical pharmacists after pharmaceutical consultation. According to the Pharmaceutical Care Network Europe （PCNE） classification system V 9.1，the existing drug-related problems （DRPs）were classified and summarized. The effectiveness and safety evaluation，medication education and other measures were provided ，and the acceptance of intervention was analyzed at the same time. RESULTS A total of 100 patients were included ，including 54 males and 46 females. The average age was （60.21±9.69） years，the average number of chronic diseases was （2.84±0.83），and the median number of drugs was 5.00. Among them ，110 treatment drug deviations were found in 74 patients，involving 10 categories and 61 drugs. Top three drugs in the list of accumulative drug deviation were cardiovascular system drugs （35 deviations），digestive medicine drugs （16 deviations）and endocrine system drugs （15 deviations）. The above treatment drug deviation may cause 122 DRPs， mainly “treatment effectiveness”problems（74 DRPs），and the causes were “inappropriate medication time ormedication interval ”（32 DRPs）， followed by “inappropriate drug combination ”（10 DRPs）. Interventions to DRPs mainly concentrated on patient level ，drug level （58）and doctor level （58），155 of which （84.70％）were fully accepted and implemented. CONCLUSIONS Some patients have a weak awareness of medications according to doctor ’s advice；drug reconciliation led by clinical pharma- cists at admission can fully understand the potential drug problems of patients ，and help doctors improve the drug compliance of patients and ensure their medication safety .
Résumé
Objective To explore the monitoring results on serum concentration of valproic acid in 78 patients with epilepsy for promoting the clinical application and improving the curative effect of serum concentration.Methods The serum concentration of valproic acid was determined by fluorescence polarization immunoassay (FPIA). The serum concentration of valproic acid in 78 cases were analyzed,and the clinical efficacy and adverse reaction were observed. Results Among 78 cases, there were 55 cases (70.0%) whose serum concentration were in normal range,21 cases(27.0% ) in low range and 2 cases(3. 0% ) in high range. The clinical effective rate in 50～100mg/L group, ＜ 50mg/L group and ＞ 100mg/L group were 90.9% ,61.9% and 50.0%. The rate of adverse reaction in 50 ～ 100mg/L group, ＜ 50mg/L group and ＞ 100mg/L group were 1. 8%, 9. 5% and 100%.Conclusion There were significant individual differences among patients in serum concentration of valproic acid. Monitoring on serum concentration of valproic acid was the important measure which provide the basis for adopting individualizede administration and ensure the clinical effect and safety in the medical care.
Résumé
OBJECTIVE: To establish the HPLC method for the content determination of baicalin in Xiaoer zhike granule. METHODS: YWG C18 (150 mm?4.6 mm,10 ?m) column was used and the mobile phase consisted of methnol-water-phosphoric acid (47 ∶ 53 ∶ 0.2) with the flow rate of 2.5 mL?min-1. The detection wavelength was set at 280 nm and injection volume was 10 ?L. RESULTS: The linear range of baicalin was 25～200 ?g?mL-1(r=0.999 6) with an average recovery of 99.57%(RSD=1.9%,n=6). CONCLUSION: This method is sensitive, simple and accurate for the quality control of Xiaoer zhike granule.